Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
<p>Abstract</p> <p>Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiv...
Main Authors: | Papanicolaou Sotiria, Athanasakis Kostas, Ollandezos Markos, Kousoulakou Hara, Geitona Maria, Kyriopoulos Ioannis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-06-01
|
Series: | Annals of General Psychiatry |
Online Access: | http://www.annals-general-psychiatry.com/content/8/1/15 |
Similar Items
-
Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
by: Papanicolaou Sotiria, et al.
Published: (2008-08-01) -
Community acquired pneumonia: a cost-of-illness analysis in Greece
by: Panagiota Naoum, et al.
Published: (2020-06-01) -
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01) -
A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
by: Ali Abdall-Razak, et al.
Published: (2019-09-01) -
Paliperidone extended-release: does it have a place in antipsychotic therapy?
by: Carlos Sch&ouml;nfeldt-Lecuona, et al.
Published: (2011-03-01)